Clinical trials: Chorioretinal Vascular Disease
Chorioretinal Vascular Disease
A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)
The primary objective of this study is to is to assess the ability of retina specialists to successfully administer, via an intravitreal (IVT) injection, a 2 mg dose of ABP 938, using the ABP 938 aflibercept prefilled syringe…
- Trial name
- NCT05704725
- Testing
- ABP 938, Aflibercept
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Amgen
Chorioretinal Vascular Disease
Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe
The primary objective of the study is to determine if the pre-filled syringe (PFS) supports successful preparation and accurate administration of an aflibercept injection.
- Trial name
- NCT03767738
- Testing
- Intravitreal Aflibercept Injection (IAI)
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Regeneron Pharmaceuticals